Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Lipophagy, the selective degradation of lipid droplets (LDs) by autophagy, has the potential to ameliorate neurodegenerative diseases such as Parkinson’s (PD) and Alzheimer’s (AD), wherein LD accumulation has been linked to the exacerbation of the proteinopathy component of neurodegeneration. Pharmacological lipophagy inducers remain scarce. We previously identified AA-20 as a novel autophagy activator that acts independently of mTORC1 inhibition, thereby providing a means of stimulating autophagy while avoiding the immunosuppressive side effects associated with direct mTORC1 inhibition. Prior work also showed that AA-20 treatment reduces PolyQ aggregate levels in several C. elegans tissues. Here, we demonstrate that AA-20 enhances LD recruitment to autophagosomes and promotes LD degradation via lysosomal acid lipase activation in murine hippocampal neuronal cells, consistent with lipophagy activation. In human Swedish Amyloid Precursor Protein mutated cerebral organoids, two weeks of AA-20 treatment normalized aberrant lipidomic profiles by selectively reducing various disease-associated lipids, while also correcting the AD-associated electrical hyperexcitability phenotype. Moreover, we identified cyclin-dependent kinase 5 (CDK5), a neuronal kinase linked to AD hyperexcitability and PD pathology, as a target of AA-20. AA-20-induced autophagy and lipid clearance in HT22 cells require CDK5. In a neuronal seeding model of α-synuclein pathology, AA-20 reduced pS129-α-synuclein levels. Collectively, these findings indicate AA-20 can promote lipophagic clearance of LDs and mitigate multiple cellular phenotypes associated with lipidopathy and proteinopathy in neurodegenerative disease models.

SIGNIFICANCE

Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are associated with impaired autophagy and abnormal lipid droplet (LD) accumulation. Few small molecules enhance neuronal lipid clearance without inhibiting mTORC1, but chronic blockade of which is associated with immunosuppressive and metabolic side effects. This study shows that AA-20, an mTORC1-independent autophagy activator, promotes lipophagic LD clearance in neuronal cells and reduces selected disease-associated lipids in human Alzheimer’s cerebral organoids in a lysosomal acid lipase-dependent manner. AA-20 binds CDK5 and appears to modulate, rather than classically inhibit, this neuron-enriched kinase. In an exploratory Parkinson’s neuron model, AA-20 also reduced pathological α-synuclein phosphorylation. These findings support further investigation of AA-20 as a tool to probe neuronal lipid clearance and neurodegeneration-associated phenotypes.

Article activity feed

  1. Authors used Purified anti-α-Synu from #BioLegend in their study. Including #RRIDs will make this less ambiguous. SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #OpenScience #methodsmatter

  2. Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes #NeuroDegeneration 🧪🧠 https://www.biorxiv.org/content/10.64898/2026.10.30.760220v1

  3. Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes https://www.biorxiv.org/content/10.64898/2026.10.30.760220v1

  4. Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes https://www.biorxiv.org/content/10.64898/2026.10.30.760220v1